PMID: 2096408Jan 1, 1990Paper

Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia

Psychopharmacology
M W KellyS V Arndt

Abstract

Twenty-nine hospitalized patients suffering acute exacerbations of schizophrenia were treated for 2 weeks with fixed daily oral doses of haloperidol prospectively calculated to achieve a haloperidol plasma concentration of either 8-18 ng/ml or 25-35 ng/ml. Reduced haloperidol as well as haloperidol concentrations were assayed to determine if the former enhanced the predictability of response. Wee 2 haloperidol plasma concentrations were negatively correlated to clinical response as measured by the percentage change in the BPRS score from baseline (r = -0.43, P less than 0.05). In contrast, week 2 plasma concentrations of reduced haloperidol, total haloperidol (haloperidol + reduced haloperidol), and reduced haloperidol/haloperidol ratio did not correlate with the change in the BPRS score. Chi-square analysis concluded that patients with ratios greater than one were no less likely to be treatment responders (less than 25% improvement in BPRS from baseline and week 2 BPRS less than 55) than those with ratios less than one. Although these data lend additional support to reports of a curvilinear relationship between haloperidol plasma concentration and clinical response, they also suggest that reduced haloperidol plasma concentrati...Continue Reading

References

Dec 1, 1990·Journal of Clinical Psychopharmacology·W CoryellD D Miller
Jun 1, 1990·Journal of Clinical Psychopharmacology·D D MillerS V Arndt
Jan 1, 1985·The International Journal of Social Psychiatry·A W Burke
May 1, 1988·Drug Intelligence & Clinical Pharmacy·J J SramekR Hahn
Jan 1, 1988·Schizophrenia Bulletin·D G KirchR J Wyatt
Dec 1, 1987·Journal of Clinical Psychopharmacology·M ShostakS Curran
Oct 1, 1987·Journal of Clinical Psychopharmacology·K K MidhaG McKay
Dec 1, 1987·Archives of General Psychiatry·R C Smith
Jan 1, 1983·Psychopharmacology·M L MavroidisD L Garver
Jan 1, 1984·European Archives of Psychiatry and Neurological Sciences·P LinkowskiJ Mendlewicz
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·H ItohK Ichikawa
Jun 1, 1984·Journal of Clinical Psychopharmacology·L EreshefskyN R Burch

❮ Previous
Next ❯

Citations

Jun 1, 1994·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·W H ChangC P Chien
Jun 26, 2007·Acta Pharmacologica Sinica·Wei-hua GuGuo-zhang Jin
Jan 1, 1994·Drug Metabolism and Drug Interactions·M W JannW H Chang
Feb 1, 1994·Mayo Clinic Proceedings·G M Lawson
Aug 29, 2013·The Cochrane Database of Systematic Reviews·Lorna DonnellyClive E Adams
Mar 11, 2003·The Journal of Pharmacy and Pharmacology·Hikaru KoyamaKenji Nakajima
Aug 14, 2003·Fundamental & Clinical Pharmacology·Irismar Reis de OliveiraNalinee Poolsup

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Progress in Neuro-psychopharmacology & Biological Psychiatry
C AltamuraS R Bareggi
The British Journal of Psychiatry : the Journal of Mental Science
M H Abenson
European Archives of Psychiatry and Neurological Sciences
A E Balant-GorgiaG Garrone
© 2021 Meta ULC. All rights reserved